Eli Lilly and CoXTER:LLY +1.52%85 FCF Margin % is 14.16% as of Mar. 2026, which is 11% below its 10-year median of 15.87. GuruFocus rates XTER:LLY with a GF Score™ of 85/100 and a GF Value™ of €1,210.00 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 958 Drug Manufacturers companies, Eli Lilly and Co ranks better than 80.06% on this metric.
The historical rank and industry rank for Eli Lilly and Co's FCF Margin % or its related term are showing as below:
XTER:LLY'
s FCF Margin % Range Over the Past 10 Years
Min: -9.24 Med: 15.87 Max: 19.02
Current: 14.32
During the past 13 years, the highest FCF Margin % of Eli Lilly and Co was 19.02%. The lowest was -9.24%. And the median was 15.87%.
XTER:LLY's FCF Margin % is ranked better than 80.06% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs XTER:LLY: 14.32
Eli Lilly and Co FCF Margin % Related Terms
Eli Lilly and Co FCF Margin % Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:LLY vs JNJ, ABBV, MRK: FCF Margin % Comparison
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co (XTER:LLY) has a FCF Margin % of 14.16% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Eli Lilly and Co and its competitors. This is 11% below median its historical median of 15.87. According to the industry distribution chart, Eli Lilly and Co ranks #191 out of 958 companies in the Drug Manufacturers industry, placing it in the top 19.9%.
Is Eli Lilly and Co's FCF Margin % too high?
Eli Lilly and Co's current FCF Margin % of 14.16% is 11% below median its 10-year median of 15.87. The Drug Manufacturers industry median FCF Margin % is 2.51. Eli Lilly and Co's value of 14.16% is 464.1% above this industry median. Based on the distribution chart, Eli Lilly and Co ranks #191 out of 958 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's FCF Margin % compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #191 out of 958 companies for FCF Margin %. This places Eli Lilly and Co in the top 20% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.51. Eli Lilly and Co's value of 14.16% is 464.1% above this benchmark. While the company's 10-year median is 15.87 vs. the industry median of 2.51, Eli Lilly and Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current FCF Margin % of 14.16% is 464.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current FCF Margin % is 14.16%, which is 11% below median its own 10-year median of 15.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XTER:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is €1,210.00, compared to a current price of €980.10 — trading 19% below its estimated fair value. The current FCF Margin % is 14.16%, which is 11% below median its 10-year median of 15.87 and 464.1% above the Drug Manufacturers industry median of 2.51. Eli Lilly and Co's overall GF Score™ is 85/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Eli Lilly and Co (XTER:LLY), the current FCF Margin % is 14.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (XTER:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of €980.10 is trading 19% below its estimated GF Value™ of €1,210.00.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for XTER:LLY:
FCF Margin %: 14.16% (11% below median its 10-year median of 15.87)
GF Value™: €1,210.00 vs. price of €980.10 (19% below fair value)
Industry Position: 464.1% above the Drug Manufacturers median (#191 of 958)
No single metric tells the full story. See the XTER:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
85GF Score
Get the complete analysis for XTER:LLY
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:LLY has been successfully added to your 
